tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cellebrite Announces Participation in the 26th Annual Needham Growth Conference

Cellebrite Announces Participation in the 26th Annual Needham Growth Conference

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 11, 2024 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the Company will participate in the upcoming 26th Annual Needham Growth Conference. Relevant details include:

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Date: January 18, 2024
Conference: Needham & Co. 26th Annual Growth Conference
Presentation Time: 1:30 p.m. ET
Format Fireside Chat
Event URL: https://investors.cellebrite.com/events/event-details/needham-company-26th-annual-growth-conference
Cellebrite Executives: Dana Gerner, chief financial officer
  Andrew Kramer, vice president, investor relations


About Cellebrite

Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigation platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Investor Relations
Andrew Kramer
Vice President, Investor Relations
[email protected]
+1 973.206.7760

Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations
[email protected]
+1 404.804.5910

Disclaimer & DisclosureReport an Issue

1